Minimal residual disease status is the prognostic determinant following high‐dose treatment for patients with multiple myeloma
Cancer Medicine · 2023
DOI: 10.1002/cam4.6640 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Hareth Nahi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Institution for biomedicine and clinical science, Linköping, Sweden. Hauptthemen laut MEDLINE: Multiple Myeloma, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The presence of minimal residual disease (MRD+) following autologous stem cell transplantation (ASCT) in multiple myeloma represents a poor prognostic factor for progression‐free survival (PFS) and overall survival (OS).
Methods
At our department, we recommend lenalidomide maintenance for patients who are MRD+ after ASCT, while MRD‐negative (MRD−) patients, after information about the national guidelines, were not advised to follow this regimen.
Results
Out of the total 228 patients, 175 received ASCT following first‐line induction (MRD− 92 (53%), MRD+ 83 (47%), at 2 months post‐ASCT), while 53 underwent ASCT after second‐line treatment (MRD− 27 (51%), MRD+ 26 (49%), at the same time point). Comparatively, MRD− patients who did not receive maintenance demonstrated better OS than MRD+ patients who received upfront ASCT and maintenance treatment (96% vs. 86%, p = 0.030, at 3 years). However, nonsignificant difference was found in PFS (76% vs. 62%, at 3 years). Furthermore, second‐line ASCT, MRD− non‐maintained patients exhibited significantly better PFS than MRD+ (71% vs. 27%, p > 0.001, at 3 years). However, OS was better but nonsignificant (96% vs. 76%, at 3 years). Fluorescence in situ hybridization (FISH) analysis was performed on 141 out of the 228 patients. Of these, 85 (60%) patients were deemed standard risk (SR), and 56 (40%) were classified as high risk (HR). In the SR cohort, MRD− patients exhibited better PFS and OS than MRD+ patients (71% vs. 59% and 100% vs. 85%, respectively). In the HR cohort, the MRD− patients showed superior PFS but similar OS compared to MRD+ patients (66% vs. 42% and 81% vs. 80%, respectively).
Conclusions
Our results indicate that being MRD− is a more crucial prognostic factor for the 3‐year PFS and OS than the presence of high‐risk cytogenetic markers or undergoing maintenance treatment. The latter appears insufficient, particularly for MRD+ patients following ASCT in the second‐line setting, suggesting that these patients may require a more intensive treatment approach.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Institution for biomedicine and clinical science, Linköping, Sweden.
- Center for Hematology and Regenerative Medicine, Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden.
- Department of Medicine, Stockholm, Sweden.
ORCID-Profile: Love Tätting, Muhammad Kashif
Zitieren
APA
Nahi, H., Afram, G., Uttervall, K., Lockmer, S., Tätting, L., Gahrton, G., Kashif, M., Alici, E., Stromberg, O., Klimkowska, M., & Lund, J. (2023). Minimal residual disease status is the prognostic determinant following high‐dose treatment for patients with multiple myeloma. Cancer Medicine. https://doi.org/10.1002/cam4.6640
Vancouver
Nahi H, Afram G, Uttervall K, Lockmer S, Tätting L, Gahrton G, et al. Minimal residual disease status is the prognostic determinant following high‐dose treatment for patients with multiple myeloma. Cancer Medicine. 2023. doi:10.1002/cam4.6640
BibTeX
@article{Nahi2023,
author = {Nahi, Hareth and Afram, Gabriel and Uttervall, Katarina and Lockmer, Sandra and Tätting, Love and Gahrton, Gösta and Kashif, Muhammad and Alici, Evren and Stromberg, Olga and Klimkowska, Monika and Lund, Johan},
title = {Minimal residual disease status is the prognostic determinant following high‐dose treatment for patients with multiple myeloma},
journal = {Cancer Medicine},
year = {2023},
doi = {10.1002/cam4.6640}
}
EUVIMED